Medica is seizing on people's comfort with at-home COVID-19 testing with a new option to identify risks for chronic kidney disease.
The Minnesota health insurer announced Thursday that it is sending urine tests to nearly 50,000 members in Minnesota, Wisconsin and the Dakotas who have diabetes or hypertension. Plans for at-home diagnosis of all kinds of conditions have emerged since the latest pandemic wave, when people emptied pharmacy shelves of rapid COVID-19 tests.
Annual tests are recommended for people at heightened risk for kidney disease, but many don't even see doctors, said Dr. David Webster, Medica's chief clinical officer. "We know that so many people don't get the screening that they need, so let's make it easier for them."
Early identification can prompt people to make changes before kidney damage requires costly and invasive treatments such as dialysis, or leads to heart problems. The Healthy.io test remains experimental in the United States, and is being sent to Medica members as part of a study to gauge public interest while the Food and Drug Administration reviews it.
The test works by having mobile phone apps scan urine samples for discoloration that suggests abnormal protein levels. Results are provided instantly. Medica is hoping for more than 30% participation.
Home diagnostic testing was nudging along before the pandemic, beyond its long-standing use for pregnancy and blood sugar. Mayo Clinic researchers created Cologuard, a test in lieu of a colonoscopy where people obtain stool samples and mail them in to assess colon cancer risks. In recent weeks, multiple companies have announced plans to create home tests or expand access to existing tests for everything from fertility to iron levels to cancer.
Quest Diagnostics expects revenue from its consumer-testing service to almost quadruple from 2021 to 2025. Labcorp last month launched an OnDemand platform where people can buy tests online or schedule them in affiliated labs, pharmacies and clinics.
Home testing "is going to be dramatically accelerated in the wake of the pandemic," said Dr. Bill Morice, president of Mayo Clinic Labs and chair of Mayo's pathology department. Home testing was the top topic last week when he attended the annual meeting of the American Clinical Laboratory Association.